A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection by Morris, Shaun K et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
A meta-analysis of the effect of antibody therapy for the prevention 
of severe respiratory syncytial virus infection
Shaun K Morris1, Biljana Dzolganovski2, Joseph Beyene2 and Lillian Sung*2,3
Address: 1Pediatric Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 2Child Health Evaluative Sciences 
Hospital for Sick Children, Toronto, ON, Canada and 3Division of Haematology/Oncology Hospital for Sick Children, University of Toronto, 
Toronto, ON, Canada
Email: Shaun K Morris - shaun.morris@utoronto.ca; Biljana Dzolganovski - biljana.dzolganovski@sickkids.ca; 
Joseph Beyene - joseph@utstat.toronto.edu; Lillian Sung* - lillian.sung@sickkids.ca
* Corresponding author    
Abstract
Background: The primary objective of this meta-analytic study was to determine the impact of
RSV-IGIV and palivizumab on risk of respiratory syncytial virus (RSV)-related hospitalization.
Secondary objectives were to determine if antibody therapy decreases the risk of RSV infection,
intensive care admission, mechanical ventilation, and mortality in high risk infant populations.
Methods: We performed searches of electronic data bases from 1966 to April 2009. Inclusion and
exclusion criteria were defined a priori. Inclusion criteria were as follows: 1) There was
randomization between polyclonal or monoclonal antibodies and placebo or no therapy, and 2)
Polyclonal or monoclonal antibodies were given as prophylaxis.
Results: Of the six included studies, three utilized RSV-IGIV (total of 533 randomized to treatment
groups) and three utilized palivizumab (total of 1,663 randomized to treatment groups). The
absolute risk of hospitalization in the control arms was 12% and overall RR for all 2,196 children
who received one of the antibody products was 0.53 (95% CI 0.43, 0.66), P < 0.00001. When
looking only at the children who received palivizumab, the RR for hospitalization was 0.50 (95% CI
0.38, 0.66), P < 0.00001. For the children receiving RSV-IGIV, the RR for hospitalization was 0.59
(95% CI 0.42, 0.83, P < 0.002). The use of palivizumab resulted in a significant decrease in admission
to the ICU (RR 0.29 (95% CI 0.14, 0.59; P = 0.0007). There was no significant reduction in the risk
of mechanical ventilation or mortality with the use of antibody prophylaxis. Infants born at less than
35 weeks gestational age, and those with chronic lung and congenital heart disease all had a
significant reduction in the risk of RSV hospitalization with children born under 35 weeks
gestational age showing a trend towards the greatest benefit.
Conclusion: Both palivizumab and RSV-IGIV decrease the incidence of RSV hospitalization and
ICU admission and their effect appears to be qualitatively similarly. There was neither a statistically
significant reduction in the incidence of mechanical ventilation nor in all cause mortality. This meta-
analysis separately quantifies the impact of RSV-IGIV and palivizumab on various measures of severe
RSV disease and builds upon a previous study that was only able to examine the pooled effect of
all antibody products together.
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Background
Respiratory syncytial virus (RSV) is a ubiquitous envel-
oped RNA paramyxovirus. Two strains, subtypes A and B,
have been identified and often circulate concurrently in
annual epidemics. In temperate climates, peak incidence
occurs in the winter and early spring months. RSV is the
most important cause of bronchiolitis and viral pneumo-
nia in infants and young children. Over half of all infants
in the United States are infected in their first year of life
and nearly 100% have been infected by the age of two [1].
Humans are the only known reservoir for RSV and trans-
mission is via direct or close contact with contaminated
secretions.
Most healthy term infants do not require hospitalization
as a result of RSV infection and mortality in these infants
is less than 1%. However infants who are pre-term or have
underlying chronic conditions including chronic lung dis-
ease (CLD) or congenital heart disease (CHD) are at
higher risk for severe disease. Hospitalization and mortal-
ity in these higher risk groups is thought to be approxi-
mately 10% and 3% respectively [2,3].
The absence of a vaccine against RSV infection led to stud-
ies examining the effectiveness of passive antibody prepa-
rations. Two RSV passive antibody preparations were
originally licensed. RSV immune globulin (RSV-IGIV)
(RespiGam, MedImmune, Gaithersburg, MD), an intrave-
nously administered immune globulin product derived
from pooled adult human plasma selected for high titers
of neutralizing antibody against RSV, was approved by the
United States Federal Drug Administration (FDA) in Jan-
uary 1996 for use in infants and children younger than 24
months with CLD or a history of premature birth (< 35
weeks of gestation). In mid 1998, the FDA approved the
use of palivizumab (Synagis, MedImmune, Gaithersburg,
MD), a humanized monoclonal antibody directed against
the RSV fusion protein, for the reduction of severe lower
respiratory tract RSV infection in high risk infants and
children. Palivizumab is administered intramuscularly on
a monthly basis during the RSV season.
Single randomized trials have consistently showed that
prophylaxis with RSV-IGIV and palivizumab can reduce
hospitalization. However, these trials were not powered
to examine more rare outcomes such as need for intensive
care admission, need for mechanical ventilation, and
mortality, nor were they powered for subgroup (prema-
ture, CLD, CHD) analysis. A previous meta-analysis has
been published that concluded that RSV-IGIV and paliviz-
imab significantly decreased the incidence of hospitaliza-
tion and intensive care admission due to RSV infection
but had no effect on incidence of mechanical ventilation
or mortality [4]. However, this meta-analysis only
included one study of palivizumab and was thus unable
to examine the effect of the two antibody products. Addi-
tional randomized trials of palivizumab have been pub-
lished since the original meta-analysis. We hypothesized
that updating this meta-analysis and combining results of
all randomized trials may be able to demonstrate whether
prophylaxis with these agents can reduce severity of dis-
ease in high risk populations (i.e. premature infants and
infants with CHD). Therefore, our primary objective was
to determine the impact of RSV-IGIV and palivizumab on
risk of RSV-related hospitalization. As the primary rand-
omized controlled studies were not powered to show
effect on other measures of severe RSV disease, our sec-
ondary objectives were to determine if antibody therapy
decreases the risk of RSV infection, intensive care admis-
sion, mechanical ventilation, and mortality in high risk
populations.
Methods
Data Sources and Searches
We developed a protocol for the review and followed
standard QUOROM reporting guidelines [5]. We per-
formed electronic searches of Ovid MEDLINE from 1966
to the end of July 2008, of EMBASE from 1980 to the end
of April 2009, and of the Cochrane Central Register of
Controlled Trials until the first quarter of 2009. The search
strategy included the following Medical Subject Heading
terms and text words: respiratory syncytial virus, bronchi-
olitis, prophylaxis, prophylactic, prevention, passive
immunization, RSVIG, synagis and palivizumab. The
search was limited to studies in humans and controlled
trials and meta-analyses. As this study is a meta-analysis of
primary studies, no specific ethical approval is required.
Study Selection
Inclusion and exclusion criteria were defined a priori.
Inclusion criteria were as follows: 1) There was randomi-
zation between polyclonal or monoclonal antibodies and
placebo or no therapy, and 2) Polyclonal or monoclonal
antibodies were given as prophylaxis. For describing rea-
sons for exclusion, we used a hierarchical system in which
reasons for exclusion were ranked in the following order:
1) Absence of placebo or no treatment arm, 2) Allocation
not randomized, 3) Polyclonal or monoclonal antibody
given as treatment rather than as prophylaxis, and 4)
Duplicate publication. There was no language restriction
for inclusion in this meta-analysis.
Two reviewers (SM and BD) independently evaluated
titles and abstracts of publications identified by the search
strategy, and any potentially relevant publication was
retrieved in full. The reviewers were not blinded to study
authors or outcomes. Final inclusion of studies into the
meta-analysis was by agreement of both reviewers. Disa-
greement was adjudicated by a third author, LS. Agree-
ment between reviewers on inclusion was evaluated using
a kappa statistic. Strength of agreement as evaluated by
the kappa statistic was defined as slight (0.00–0.20), fairBMC Infectious Diseases 2009, 9:106 http://www.biomedcentral.com/1471-2334/9/106
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(0.21–0.40), moderate (0.41–0.60), substantial (0.61–
0.80) or almost perfect (0.81–1.00) [6].
Data Extraction and Quality Assessment
The outcome measures were chosen to be representative
of severe RSV lower respiratory tract disease. These include
the primary outcome measure of hospitalization. Second-
ary outcome measures were the risk of RSV infection, and
among those with RSV disease, the risk of ICU admission,
mechanical ventilation, and mortality. Other outcome
measures included days of hospitalization, days of inten-
sive care unit admission, and days of mechanical ventila-
tion. In studies that used multiple doses of antibody
product in different arms of the study, only data for recip-
ients of 750 mg/kg of RSV-IGIV or 15 mg/kg of palivizu-
mab, the universally used dosages in clinical practice,
were abstracted. Two authors (SM and BD) independently
abstracted all data to standardized data collection forms.
Study quality was assessed using the Jadad scale [7]. The
Jadad scale was designed to examine elements of clinical
studies that may affect bias. The scale ranges from 0 to 5,
with a higher score reflecting higher quality, and examines
the adequacy of randomization, double-blinding, and
descriptions of withdrawals and dropouts.
Statistical Methods
This meta-analysis combined data at the study level and
not at the individual patient level. Outcome data were
synthesized using relative risk (RR) as the effect measure;
RR greater than 1.0 suggests that an intervention is associ-
ated with an increase in that outcome and RR less than 1.0
suggests a decrease in that outcome. Effect sizes were
weighted by the inverse of the variance.
Because we anticipated heterogeneity between studies, a
random effects model was used for all analyses [8]. Sub-
group analyses were performed for infants and children
born prematurely, with CLD, and with CHD for the out-
come of RSV hospitalization. There were insufficient
events to perform subgroup analyses for other outcomes.
We tested for heterogeneity using the Cochran Q test and
quantified the degree of heterogeneity with the I2 statistic.
The I2 statistic ranges from 0–100% and measures the
degree of inconsistency across studies in a meta-analysis
as low, moderate, and high to I2 values of 25%, 50%, and
75%, respectively [9].
Publication bias, which occurs when small studies are
published only if the results are positive, was examined
using a funnel plot. This plot displays RR on the x-axis and
the inverse of variance of the effect on the y-axis. Asymme-
try, without studies in the bottom left or right corner,
depending on the effect measure, suggests publication
bias. In the event of possible publication bias, the 'trim
and fill' technique was used to determine the impact of
such bias [10]. With this technique, outlying studies are
deleted and hypothetical negative studies with equal
weight are created to determine the robustness of the con-
clusions of the analysis. This meta-analysis was performed
using Review manager (RevMan) (Version 4.2, The
Cochrane Collaboration, Oxford, England).
Results
Study Selection and Characteristics
Figure 1 demonstrates the flow of trial identification and
selection. The original search produced a total of 1,000
articles. Following initial review of titles, 397 potentially
relevant references were identified. The abstracts of these
397 articles were reviewed and 24 full articles were
retrieved. Of these, six articles met inclusion criteria. The
characteristics of the included studies are shown in Table
1. There was complete agreement between the two review-
ers regarding articles for inclusion, with a kappa statistic of
1.00. The median validity score was 4 (range 1 to 5) on a
scale of 0 to 5 in which a higher number indicates higher
quality. Publication bias was not seen in any of the out-
comes via a visual inspection of funnel plots (data not
shown).
Of the six included studies, three utilized RSV-IGIV [11-
13] (total of 533 randomized to treatment groups) and
three utilized palivizumab (total of 1663 randomized to
treatment groups) [14-16]. The characteristics of the
included studies are shown in Table 1. One study [11] uti-
lized high dose (750 mg/kg) and low dose (150 mg/kg)
RSV-IGIV in separate treatment arms. This meta-analysis
only includes data from the high dose arm. One study
[14] was a palivizumab dose escalation trial and utilized
separate intervention arms of 3, 10, and 15 mg/kg. This
meta-analysis only includes data from the 15 mg/kg treat-
ment arm. All of the studies gave palivizumab for only
one RSV season.
Effect on Severe RSV Disease
Figure 2 illustrates the results of the effects of antibody
prophylaxis on the primary outcome of hospitalization
with confirmed RSV disease. The absolute risk of hospital-
ization in the control arms was 12% and overall RR for all
2,196 children who received one of the antibody products
was 0.53 (95% CI 0.43, 0.66), P < 0.00001; Chi2 2.97, P =
0.65, I2 = 0%. When looking only at the children who
received palivizumab, the RR for hospitalization was 0.50
(95% CI 0.38, 0.66), P < 0.00001; Chi2 0.67, P = 0.70, I2
= 0%. For the children receiving RSV-IGIV, the RR for hos-
pitalization was 0.59 (95% CI 0.42, 0.83), P < 0.002; Chi2
1.54, P = 0.46, I2 = 0%. Only one study [15] specifically
examined the effect of palivizumab in infants born
between 32 and 35 weeks gestational age and showed an
80% reduction in RSV related hospitalization (P = 0.002).BMC Infectious Diseases 2009, 9:106 http://www.biomedcentral.com/1471-2334/9/106
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The number needed to treat with palivizumab to prevent
one hospital admission was 20 (95% CI 14–33).
Table 2 illustrates the effect of prophylaxis on the second-
ary outcomes of ICU admission, mechanical ventilation,
RSV infection, and mortality. The use of palivizumab
resulted in a significant decrease in admission to the ICU
(RR 0.29 (95% CI 0.14, 0.59), P = 0.0007; Chi2 2.34, P =
0.13, I2 = 57.3%. The number needed to treat with palivi-
zumab to prevent one ICU admission was 20 (95% CI 9 –
30). Only one study examined the impact of palivizumab
on RSV infection and did not find a significant reduction
in this outcome. The use of RSV-IGIV did show a trend
towards reduced RSV infection but did not reach statistical
significance. There was no significant reduction in the risk
of mechanical ventilation or mortality with the use of
antibody prophylaxis.
Table 3 shows the results of the stratified analyses. In the
stratified analyses, infants born at less than 35 weeks ges-
tational age, and those with CLD and CHD all had a sig-
nificant reduction in the risk of RSV hospitalization with
children born under 35 weeks gestational age showing a
trend towards the greatest benefit. The relative risk for
hospitalization for premature infants receiving palivizu-
mab was 0.2 (0.09, 0.46), P = 0.0001; however, only one
study [15] provided data for this analysis. The relative risk
favoring prophylaxis in premature infants receiving RSV-
IGIV was 0.45 (0.18, 1.11), P = 0.08, I2 = 67.9%.
The overall rate of mortality was low in all groups and the
majority of deaths were unrelated to RSV infection or anti-
body prophylaxis. The impact of antibody prophylaxis on
mortality is shown in Tables 2 and 4. With the exception
of Subramanian 1998 [14], all included studies provided
data on duration of RSV hospitalization. However, as no
measure of variance was provided for these outcomes,
these data were not able to be included in this meta-anal-
ysis. However, duration of hospital stay is a surrogate
marker of disease severity and thus the data is presented
in Table 5.
Adverse effects associated with palivizumab were rare and
no specific adverse effect was statistically more significant
in the treatment groups as compared to the control groups
[15,16]. Adverse effects in RSV-IGIV recipients included
fluid overload [11-13], decreases in oxygen saturation or
cyanosis [11,13], fever [11,12] and respiratory distress
[11,12]. In Simoes 1998 [13], there were 11 instances of
unexpected cyanosis in 111 children with right to left
shunts or complex cardiac defects in RSV-IGIV recipients
compared to 1 such event in 83 children with similar car-
diac defects in the control group (p = 0.03). In 8 of the 11
cases, the unanticipated cyanosis led to urgent surgery.
Discussion
We found that both palivizumab and RSV-IGIV decrease
the incidence of RSV hospitalization and ICU admission
and their effect appears to be qualitatively similar. This
study builds on a previous meta-analysis [4] through the
addition of two additional randomized clinical trials. In
contrast to this earlier meta-analysis which included only
one palivizumab study, we have been able to separately
examine the effect of palivizumab and RSV-IGIV on RSV
disease severity. The numbers needed to treat with palivi-
zumab to prevent one RSV-related hospitalization and
one ICU admission were 20 (95% CI 14 – 33) and 20
(95% CI 9 – 50) respectively. Using pooled date for paliv-
izumab and RSV-IGIV, Wang et al.[4] found that the num-
bers needed to treat to prevent one hospitalization and
one ICU admission were 17 and 50 respectively. Our
study did not find a statistically significant reduction in
either the incidence of mechanical ventilation or in all
cause mortality. However, due to the rare nature of these
events, small differences in these outcomes might not be
detectable by our meta-analytic study.
Table 1: Study Characteristics
Study Intervention # Treated # Controls Patient Population Double Blinding
Groothuis 1993 RSV-IGIV 750 mg/kg 81 89 Premature, CLD, CHD No
PREVENT 1997 RSV-IGIV 750 mg/kg 250 260 Premature, CLD Yes
Simoes 1998 RSV-IGIV 750 mg/kg 202 214 CHD No
Subramanian 1998 Palivizumab 15 mg/kg 22 20 Premature, CLD Yes
IMPACT 1998 Palivizumab 15 mg/kg 1002 500 Premature, CLD Yes
Feltes 2003 Palivizumab 15 mg/kg 639 648 CHD YesBMC Infectious Diseases 2009, 9:106 http://www.biomedcentral.com/1471-2334/9/106
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Palivizumab appeared to be safe and was not associated
with any severe adverse events in any of the trials includ-
ing in children with CHD. However, in post-marketing
surveillance, palivizumab was very rarely associated with
both anaphylactic (<1 in 100,000 patients) and hypersen-
sitivity (1 in 1,000 patients) reactions [17]. These reac-
tions may be more common if palivizumab is used in a
second season and thus would be exceedingly unlikely to
be seen in a study using the product over a single season.
Conversely, RSV-IGIV appeared to be related to significant
adverse events in infants and children with certain types of
CHD. Additional disadvantages to RSV-IGIV include the
need for intravenous access as well as the risk of infectious
disease transmission and anaphylaxis that exists with any
immune globulin product. Largely due to safety concerns
of RSV-IGIV in children with CHD, and the availability of
a safe and effective alternative prophylactic therapy, RSV-
IGIV is no longer commercially available in the United
States or Canada.
Palivizumab has only been evaluated in randomized con-
trolled trials in specific groups of infants. While other
groups of infants may also gain protection against severe
RSV disease from this product, this has not been formally
studied. Due to the high cost of palivizumab, published
guidelines restrict recommendations for use to the highest
risk subgroups of infants and children for whom the evi-
dence for effectiveness is strongest. Palivizumab is cur-
rently recommended by the American Academy of
Pediatrics for infants and children born at less than 32
Flow diagram of trial identification and selection Figure 1
Flow diagram of trial identification and selection.
Full articles retrieved for detailed 
evaluation 
(n =24) 
Excluded (n = 18) 
Absence of placebo/no-treatment group: 15 
Allocation not randomized:0 
Polyclonal or monoclonal antibody given as treatment rather than prophylaxis:1 
Population does not consist of infants and young children under 48 months of age:0 
Duplicate publication:2 
Excluded by review of abstract:  did not fulfill inclusion/exclusion criteria 
(n = 373)
Studies included in meta-analysis 
(n = 6) 
Potentially relevant references identified 
and screened 
(n =397) BMC Infectious Diseases 2009, 9:106 http://www.biomedcentral.com/1471-2334/9/106
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weeks gestation, and infants born at less than 35 weeks
gestation who are younger than 6 months at the begin-
ning of RSV season and have two or more risk factors
(child care attendance, school-aged siblings, exposure to
environmental air pollutants, congenital abnormalities of
the airways, or severe neuromuscular disease) for severe
bronchiolitis. Palivizumab is also recommended for chil-
dren who are 24 months of age or younger with hemody-
namically significant cyanotic, acyanotic congenital heart
disease, or CLD requiring medical therapy within the pre-
vious 6 months [18]. Similarly, in Canada, the Canadian
Pediatric Society (CPS) recommends palivizumab for
children with CLD and those born at less than 32 weeks
gestation. The CPS also recommends palivizumab in the
winter season be considered in those less than two years
of age with hemodynamically significant CHD [19].
The cost effectiveness of palivizumab will vary by location
based on the price of the drug and other health care serv-
ices in a given area and the hospital and societal based
cost metrics that are used. The cost that is deemed 'effec-
tive' may also differ across regions and countries. As a
result, studies that attempt to determine cost effectiveness
of palivizumab may not be generalizable outside of the
Effect of Palivizumab and RSV-IGIV on RSV Hospitalization Figure 2
Effect of Palivizumab and RSV-IGIV on RSV Hospitalization.
Study  Treatment  Control RR (random)  Weight RR (random)
 n/N n/N  95% CI  %  95% CI
Palivizumab
      48/1002            53/500   31.80     0.45 [0.31, 0.66]   IMpact-RSV     
  1.29     0.91 [0.14, 5.86]         2/22               2/20   Subramanian 
      34/639             63/648   27.67     0.55 [0.37, 0.82]   Feltes 
 Subtotal (95% CI) 1663               1168  60.77     0.50 [0.38, 0.66]
 Total events: 84 (Treatment), 118 (Control)
 Test for overall effect: Z = 4.99 (P < 0.00001)
RSV IGIV
  5.88     0.37 [0.15, 0.88]         6/81              18/89   Groothuis 
      20/250             35/260   16.50     0.59 [0.35, 1.00]   PREVENT Study Group 
 16.86     0.70 [0.42, 1.16]        21/202             32/214   Simoes 
 Subtotal (95% CI) 533                563  39.23     0.59 [0.42, 0.83]
 Total events: 47 (Treatment), 85 (Control)
 Test for overall effect: Z = 3.05 (P = 0.002)
2196               1731 100.00     0.53 [0.43, 0.66] Total (95% CI)
 Total events: 131 (Treatment), 203 (Control)
 Test for overall effect: Z = 5.80 (P < 0.00001)
0.1 0.2 0.5  1  2  5  10
 Favours treatment  Favours control
Table 2: Primary and Secondary Outcome Measures with Prophylaxis versus Placebo
Outcome Measure RR all Antibody Prophyaxis RR Palivizumab RR RSV-IGIV
RSV Hospitalization 0.53 (0.43, 0.66), P < 0.00001 0.50 (0.38, 0.66); 3 14,15,16 studies, 1663 
treated, P < 0.00001
0.59 (0.42, 0.83); 3 11,12,13 studies, 533 
treated, P = 0.002
ICU Admission 0.39 (0.21, 0.70), P = 0.002 0.29 (0.14, 0.59); 2 15,16 studies, 1641 
treated, P = 0.0007
0.50 (0.24, 1.04); 311,12,13 studies, 533 
treated, P = 0.06
Mechanical Ventilation 0.76 (0.43, 1.36), P = 0.36 1.10 (0.20, 6.09); 215,16 studies, 1641 
treated, P = 0.91
0.77 (0.33, 1.79); 311,12,13 studies, 533 
treated, P = 0.55
RSV Infection 0.78 (0.60, 1.01), P = 0.06 0.45 (0.09, 2.22); 114 study, 22 treated, P = 
0.33
0.79 (0.61, 1.03); 211,13 studies, 283 
treated, P = 0.08
All Cause Mortality 0.95 (0.55, 1.65), P = 0.86 0.71 (0.42, 1.19); 215,16 studies, 1641 
treated, P = 0.19
1.53 (0.65, 3.61); 311,12,13 studies, 533 
treated, P = 0.33BMC Infectious Diseases 2009, 9:106 http://www.biomedcentral.com/1471-2334/9/106
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area in which they were conducted. A recent Canadian
study [20] determined the incremental cost-effectiveness
of palivizumab in pre-term infants born at 32 to 35 weeks
gestational age to be $20,924 per quality adjusted life year
a value which is considered cost-effective in Canada.
However, a very comprehensive systematic review [21] of
all published cost-effectiveness studies (including in Can-
ada, the United Kingdom, and the United States) con-
cluded that palivizumab does not represent good value
when used unselectively in preterm infants without CLD
or children with CLD or CHD. Our study adds to the pre-
vious meta-analysis [4] in that it increases the precision of
treatment effect estimates and increases the statistical
power. Our study found the number needed to treat with
palivizumab to prevent one ICU admission to be 20 in
contrast to Wang et al.[4] who found that 50 infants
needed to be treated with antibody product (RSV-IGIV or
palivizumab). These results should prove useful in per-
forming more precise cost-effectiveness analysis in the
future.
A new monoclonal antibody, motavizumab, with
increased affinity for the fusion protein of RSV has
recently been developed. Motavizumab, binds to RSV
fusion protein 70-fold better than palivizumab, and has a
20-fold improvement in neutralization of RSV in vitro. In
the cotton rat model, motavizumab reduced pulmonary
RSV titers to up to 100-fold lower levels than did palivizu-
mab at equivalent concentrations. Unlike palivizumab,
motavizumab also inhibited viral replication in the upper
respiratory tract [20]. A large clinical trial comparing pal-
ivizumab to motavizumab showed a 26% decrease in the
incidence rate of RSV hospitalization with the new prod-
uct [21]. This study also demonstrated decreased RSV dis-
ease severity and decreased outpatient disease with
motavizumab. Due to its expected longer serum half life,
motavizumab may offer the opportunity for less than the
monthly dosing required of palivizumab. However, given
the expected high cost of this new product, it is unclear
whether palivizumab or motavizumab is the optimal
agent for RSV prophylaxis.
Conclusion
In conclusion, the polyclonal and monoclonal RSV anti-
body products have the ability to significantly reduce the
risk of severe RSV disease in high risk infants. This meta-
analysis separately quantifies the impact of RSV-IGIV and
palivizumab on various measures of severe RSV disease
Table 3: Stratified Analysis for RSV Hospitalization
Subgroup RR all Antibody Prophyaxis # of Studies # in Treatment Groups
Premature <35 weeks GA[11,12,15] 0.29 (0.16, 0.54) 3 624
Chronic Lung Disease (CLD)[11,12,15] 0.55 (0.38, 0.80) 3 696
Congenital Heart Disease (CHD)[11,12,16] 0.56 (0.40, 0.79) 3 865
Table 4: Summary of Mortality Data
Study Deaths Treatment Deaths Control Notes
Groothuis 1993 (RSV-IGIV) 3 0 No deaths due to RSV or RSV-IGIV
PREVENT 1997 (RSV-IGIV) 5 2 No deaths due to RSV or RSV-IGIV
Simoes 1998 (RSV-IGIV) 13 13 2 deaths in treatment group & 5 in control group due to 
respiratory causes
Subramanan 1998 (Palivizumab) 0 1 Disseminated adenovirus
IMPACT-RSV 1998 (Palivizumab) 4 5 2 deaths in treatment group occurred during RSV hospitalization
Feltes 2003 (Palivizumab) 21 27 2 deaths in treatment group and 4 deaths in control group due to 
RSVBMC Infectious Diseases 2009, 9:106 http://www.biomedcentral.com/1471-2334/9/106
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and builds upon a previous study that was only able to
examine the pooled effect of all antibody products
together. Further studies of these antibody products, and
motavizumab may further define the groups that are most
likely to benefit from their use.
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